Zacks Investment Research Lowers Neos Therapeutics Inc. (NEOS) to Sell
Neos Therapeutics Inc. (NASDAQ:NEOS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets started coverage on shares of Neos Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $21.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/zacks-investment-research-lowers-neos-therapeutics-inc-neos-to-sell.html
Neos Therapeutics (NASDAQ:NEOS) opened at 6.88 on Wednesday. The firm’s market cap is $110.56 million. Neos Therapeutics has a 52 week low of $6.33 and a 52 week high of $19.29. The firm’s 50-day moving average is $7.07 and its 200-day moving average is $8.68.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by $0.49. The business earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. On average, equities analysts anticipate that Neos Therapeutics will post ($5.39) earnings per share for the current year.
In other Neos Therapeutics news, CFO Richard I. Eisenstadt acquired 3,710 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The stock was purchased at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the acquisition, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.85% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp increased its position in shares of Neos Therapeutics by 20.0% in the first quarter. State Street Corp now owns 64,825 shares of the company’s stock worth $698,000 after buying an additional 10,786 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Neos Therapeutics by 5.4% in the first quarter. Geode Capital Management LLC now owns 38,698 shares of the company’s stock worth $417,000 after buying an additional 1,997 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock worth $353,000 after buying an additional 16,046 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock worth $267,000 after buying an additional 16,815 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock worth $2,729,000 after buying an additional 32,266 shares in the last quarter. Hedge funds and other institutional investors own 37.73% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.